ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

Only Seven Of 66 “Benign” Breast Cancer Turn Out to Be Doubtful

November 25, 1977

Clinical Trials: Breast Cancer Prevention Trial requires Fewer Participants, NCI Says

September 6, 1996

Will Insurers Pay Patient Care Costs? Stay Tuned For Act II Of This Oncodrama

July 31, 1998

Fake Avastin, Paid for by Medicare, Administered to U.S. Patients

October 3, 2014

Stand Up To Cancer Launches Immunology “Dream Team”

December 14, 2012

Take Program Direction Away From CCIRC, Form New Group for Clinical Trials, Conferees Suggest

June 6, 1975